Nathan Pennell: 3 Questions That Matter for the Next Multiple Myeloma Treatment
Nathan Pennell, Senior Vice President, Head of Global Medical Oncology at Bristol Myers Squibb, shared a post on LinkedIn:
“Years in the clinic have taught me to ask three questions about every new treatment:
- How well does it work?
- What does the safety profile look like?
- How can we work to make sure it reaches the patients who need it?
The Phase 3 EXCALIBER-RRMM results presented at IMS26 today give me real reason for optimism on all three counts. I’m genuinely excited by what they could mean for patients with relapsed/refractory multiple myeloma.
Having spent years working toward a future where more patients actually receive the medicines they need, I couldn’t be prouder to be part of a team accelerating the journey from scientific discovery to patient impact.
Thank you to the colleagues, investigators and patients advancing this critical research.”
Stay updated with Hemostasis Today.
-
Sep 28, 2026, 13:20Elif Susan Elcin։ PRP for Skin Rejuvenation – Is It Worth the Hype?
-
Sep 28, 2026, 13:07Alexandru Stieber: Looking Beyond MDS in VEXAS Syndrome
-
Sep 28, 2026, 12:53Shifa Maharani: Research Innovation and Recognition at JSMID 8th
-
Sep 28, 2026, 12:40Najmul Hasan Forhad: Platelets – The Unsung Heroes of Hemostasis
-
Sep 28, 2026, 12:29Turki Alqahtani: From Routine Testing to Specialized Hematology Diagnostics
-
Sep 28, 2026, 11:26Andra Tocarciuc: Immune TTP in 2026 – Moving Toward Plasma Exchange–Free Care
-
Sep 28, 2026, 11:00Oren Rom: Connecting Amino Acid and Lipid Metabolism in MASH
-
Sep 28, 2026, 10:38Dawn Rotellini: Advocating for Women and Girls With Bleeding Disorders
-
Sep 28, 2026, 10:18Neha Rastogi Panda: Empowering Young Women Through Health Awareness